A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jan 29, 2024
Trial Information
Current as of July 24, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two types of surgical procedures for patients with gastric cancer or cancer at the gastroesophageal junction. The study aims to find out whether a minimally invasive proximal gastrectomy (MIPG) or a minimally invasive total gastrectomy (MITG) is more effective for those diagnosed with this type of cancer. Participants will fill out a questionnaire a month before their surgery and then again at 1, 3, 6, and 12 months after the procedure to help researchers understand the outcomes and recovery experiences.
To be eligible for the study, participants must be at least 18 years old and have a confirmed diagnosis of non-metastatic gastric or gastroesophageal junction adenocarcinoma. They should also be able to read and understand English, Spanish, Japanese, or Korean. However, those with certain medical conditions, such as malabsorption syndromes or narcotic dependence, and pregnant individuals cannot participate. This trial is currently recruiting participants, and it offers an opportunity to contribute to important research while receiving standard care for their condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able to speak and read English, Spanish, Japanese or Korean
- • Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention
- • Age ≥ 18
- Exclusion Criteria:
- • Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
- • Patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent
- • Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion
- • Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Harrison, New York, United States
Middletown, New Jersey, United States
Montvale, New Jersey, United States
Commack, New York, United States
Basking Ridge, New Jersey, United States
Rockville Centre, New York, United States
Houston, Texas, United States
Patients applied
Trial Officials
Vivian Strong, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported